

Zürich, 13.09.2022



LubioScience launches antibody sequencing and production services in Switzerland

LubioScience GmbH, Switzerland's leading Life Sciences platform, announces the launch of a novel antibody sequencing and antibody production service to expand its custom services offering.

In partnership with Rapid Novor Inc., LubioScience now offers REmAb™ monoclonal antibody sequencing services to researchers in Switzerland.

REmAb™ uses next generation protein sequencing in combination with patented protein chemistry and machine learning to identify complete primary amino acid sequences from any given protein or antibody.

The sequenced antibody or protein is then recombinantly produced in a mammalian expression system. LubioScience takes advantage of its network of trusted partners to supply recombinant antibody production services with fast turnaround times and tailored project support.

“We're excited to expand our custom services portfolio by offering de novo antibody sequencing and expression services to support our clients in characterizing their valuable antibodies and in securing long-term supply” says Dr. Muriel Revol, Director of Custom Services. The complete range of LubioScience custom services is also available via [Scientist.com](https://www.scientist.com).

About LubioScience

LubioScience is Switzerland's fastest growing Life Sciences platform. We carry over 4 million products from more than 120 suppliers, including the largest portfolio of antibodies, proteins and assays kits in Switzerland. LubioScience is proud to be a carbon neutral company and we compensate our full carbon footprint by investing in multiple reforestation projects across the globe. LubioScience is a preferred supplier of the Swiss Biotech Association and a member of the [Pivotal Scientific Limited Alliance](#) and the [European Bioscience Network](#).